Seeds of power: China turns to genetic engineering to become global superpower Genevieve Donnellon-May | Think China | May 11, 2026

https://geneticliteracyproject.org/2026/05/11/seeds-of-power-china-turns-to-genetic-engineering-to-become-global-superpower/

Overmedicalization? RFK Jr.’s antidepressant crackdown raises conflict questions over his fee stake in Wisner Baum, the tort firm built on suing drug makers Joanna Mulvaney | Medical News Bulletin | May 11, 2026

https://geneticliteracyproject.org/2026/05/11/overmedicalization-rfk-jr-s-antidepressant-crackdown-raises-conflict-questions-over-his-fee-stake-in-wisner-baum-the-tort-firm-built-on-suing-drug-makers/

Experts wonder ‘Where is the CDC?’ as hantavirus outbreak unfolds The World Health Organization is playing a leading role in tackling the cruise ship outbreak

https://www.statnews.com/2026/05/09/mv-hondius-hantavirus-outbreak-cdc-takes-back-seat-to-who/ By Associated PressMay 9, 2026

What addiction medicine can teach us about depending on AI Relying on AI to reduce discomfort is very similar to relying on a substance

https://www.statnews.com/2026/05/11/ai-dependence-addiction-substances-relief-psychology/ By Jonathan AveryMay 11, 2026 Avery is vice chair for addiction psychiatry at Weill Cornell Medicine and host of the podcast Thriving With Addiction.

AI doctors should be licensed. Here’s a framework to do that Utah’s pilot program with Doctronic shows that federal action is necessary

https://www.statnews.com/2026/05/11/ai-doctors-licenses-utah-doctronic-pilot/ By Alon BergmanMay 11, 2026 Bergman is an assistant professor of medical ethics and health policy at the Perelman School of Medicine at the University of Pennsylvania.

Provider, insurer groups rush to shape No Surprises Act arbitration rules The law has protected patients, but its costs are soaring as far more disputes are funneled through arbitration

https://www.statnews.com/2026/05/11/no-surprises-act-new-rules-dispute-resolution/ By Tara BannowMay 11, 2026 Hospitals and Insurance Reporter

Medicare is spending far less than expected on new Alzheimer’s drugs Complicated use and uncertain benefits of Leqembi and Kisunla stunt uptake

https://www.statnews.com/2026/05/11/medicare-spending-less-than-expected-alzheimers-drugs-leqembi-kisunla/ By Bob HermanMay 11, 2026 Bob Herman is the author of Health Care Inc., an award-winning weekly newsletter about the business of health and medicine. Alzheimer's drug rollouts fall far below expectations Two years after Medicare officials warned that new Alzheimer’s drugs could cost the program billions, uptake of the medicines Leqembi and Kisunla have been strikingly muted, STAT’s Bob Herman writes. Medicare spent just a few hundred million dollars on the drugs through most of 2025 — a fraction of early projections — as patients and physicians grapple with complicated infusion schedules, repeated brain imaging requirements, and bleeding risks. Beyond that, there are lingering doubts about whether the treatments produce meaningful real-world benefits. "There’s no way to know," one neurologist said. "There’s no way you can judge progress with a drug that slows worsening. You can see people stabilize, but if they get worse at a slower rate, how the hell do you know?"